UCLA-led Study: Viscoelastic SynVACs Reprogram T Cell Metabolism for TCR-T Therapy
Synthetic antigen-presenting cells whose stress-relaxation kinetics are chemically tuned — while stiffness and ligand density stay constant — outperform monocyte-derived dendritic cells at enriching antigen-specific CD8+ T cells, according to a UCLA-led study published March 6. The work, posted in Nature’s preprint server by a team spanning UCLA and the University of Southern California, argues that the viscoelasticity of the activation surface — not just its biochemical signals — reprograms T cell metabolism for TCR-T manufacturing.
The study, led by Song Li and co-first authors Youcheng Yang, Yan-Ruide Li and Zeyang Liu, spans UCLA’s Bioengineering, Microbiology & Molecular Genetics, Chemical and Biomolecular Engineering, Computational Medicine, Materials Science, and Chemistry departments, plus USC’s biomedical engineering program and the Terasaki Institute.
The Tech TL;DR:
- Fast-relaxing SynVAC-pMHC amplifies TCR signaling and mTOR activity, driving mitochondrial remodeling toward a stem-like, energetically favorable metabolic state.
- TCR-T cells expanded on this platform show superior persistence and durable antitumor activity in both melanoma and ovarian cancer mouse models.
- The platform is fully synthetic and scalable — no donor-derived dendritic cells required.
The study builds on earlier work. A December 2024 paper in Nature Biomedical Engineering described a high-throughput microfluidic fabrication system for SynVACs, reporting roughly 90% CAR-transduction efficiency and substantial increases in T memory stem cells compared with rigid or elastic microspheres.
That earlier work also documented suppression of regulatory T cell formation and longer persistence in human lymphoma and ovarian cancer xenograft models. A patent application (PCT/US24/22516) was filed by Z. Liu, Y.-R. Li, L. Yang and S. Li as inventors, per the journal’s competing-interests statement.
What’s new in the current study is the metabolic mechanism. According to the abstract, fast-relaxing SynVAC-pMHC “programs antigen-specific T cells toward an energetically favorable metabolic state with enhanced stem-like properties.” The team isolated viscoelasticity as a variable by holding pMHC and co-stimulatory ligand densities fixed across all test conditions — a controlled comparison that distinguishes mechanical cue from biochemical signal.
Extended figure data published alongside the preprint show the metabolic assays directly: oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measured across multiple donors, with sequential oligomycin, FCCP, and rotenone/antimycin additions, comparing fast-relaxing (FRB), medium-relaxing (MRB), and slow-relaxing (SRB) beads against an IL-2-only control.
Intracellular lactate, TCA cycle metabolites, cofactors, and nucleotide pools were quantified by pathway. Significance was determined by one-way ANOVA, with mean ± s.e.m. reported.
Fluorescence lifetime imaging microscopy (FLIM) added single-cell resolution: UMAP plots overlay cell size, circularity, NAD(P)H intensity, redox ratio, and normalized mitochondria size across the FRB, MRB, SRB, and control groups, showing how the fast-relaxing condition shifts the population toward a distinct metabolic phenotype.
The practical payoff is manufacturing. T-cell activation requires coordinated integration of biochemical cues and physical interface properties, but the mechanistic basis linking those microenvironmental parameters to metabolic programming had remained poorly defined, per the abstract. This study fills that gap — and points toward a scalable, fully synthetic alternative to donor-derived dendritic cells, which vary batch to batch and carry contamination and consistency risk in GMP workflows.
For biotech engineering teams evaluating cell-therapy manufacturing platforms, the relevant comparison is process control. A synthetic bead with chemically tuned stress-relaxation kinetics offers reproducible mechanical parameters that primary cells cannot. Labs manufacturing TCR-T cells using synthetic viscoelastic activating cells — a scalable, fully synthetic platform — would integrate this as an activation step, expanding antigen-specific T cells with improved persistence and antitumor activity.
No clinical trial registration, manufacturing partner, or timeline for human testing appears in the available material. The preprint itself has not yet completed peer review, per its posting on Research Square.
The broader signal is that mechanobiology is moving from observation to manufacturing input. If viscoelasticity can be tuned as precisely as cytokine concentration, cell-therapy CDMOs and bioprocess engineers gain a new control variable — one that could shift yield, phenotype, and potency without touching the genetic engineering step at all.
Song Li, who led the study, is a chancellor professor and former chair of Bioengineering at UCLA, where he moved in 2016 after fourteen years on the bioengineering faculty at UC Berkeley.
Trained in mechanics and engineering science at Peking University before earning a Ph.D. in bioengineering at UC San Diego under Shu Chien, he has built his career around cell engineering, mechanobiology, biomaterials, and regenerative medicine — the same mechanobiology thread that runs through the SynVAC platform.
He has been elected a Fellow of the International Academy of Medical and Biological Engineering, the Biomedical Engineering Society, and the American Institute for Medical and Biological Engineering.
The patent filing on SynVAC suggests the UCLA team already sees a commercial path.